Prescription Drug Trandolapril and Verapamil Tablets Recalled for Subpotency
Glenmark Pharmaceuticals is recalling Trandolapril and Verapamil Extended-Release Tablets because they are subpotent—they do not contain their full specified amount of active ingredient. The issue was found during three-month stability testing.
What this means for you
Minor labeling or packaging issue, or a voluntary precautionary recall. Risk of harm is low but real — follow the manufacturer's instructions.
Our severity reasoning: FDA Class III recalls are typically scored 1 or 2 per the rubric. No reported illnesses, injuries, or deaths. The hazard is a product potency issue identified through stability testing, not a direct safety threat like contamination or allergen exposure.
Plain-English summary
Glenmark Pharmaceuticals Inc., USA is recalling Trandolapril and Verapamil Hydrochloride Extended-Release Tablets 2 mg/180 mg, 100-count bottles, distributed nationwide. The recall was initiated because stability testing revealed the tablets are subpotent—they do not contain the full specified amount of active pharmaceutical ingredient.
The affected batch is #19224744. Approximately 1,200 bottles are subject to recall. The subpotency was identified during the three-month stability testing timepoint.
Patients taking this medication should contact their pharmacy or healthcare provider regarding the recall. Consumers with questions may contact Glenmark Pharmaceuticals or the FDA for more information.
The recalled product
- Product
- TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE (TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE)
- Brand
- TRANDOLAPRIL AND VERAPAMIL HYDROCHLORIDE
- Manufacturer
- Glenmark Pharmaceuticals Inc., USA
- Category
- Drug
- Hazard
- Affected units
- 1,200
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- Batch # 19224744
UPCs (2)
- 0368462294017
- 0368462329016
Distribution
Distributed nationwide across the United States.
Related recalls
Same manufacturer · Glenmark Pharmaceuticals Inc., USA
See all →- ModerateAzelaic Acid Gel 15% Recalled Over Grainy, Gritty, or Sandy Texture
FDA (Drugs) · 2026-08-05
- ModerateAlyacen 7/7/7 birth control tablets failed total impurities specification
FDA (Drugs) · 2026-06-24
- ModerateOndansetron tablets recalled because blister packs are not fully sealed
FDA (Drugs) · 2026-01-07
- CriticalFrozen chopped methi recalled after testing positive for Salmonella
FDA (Drugs) · 2025-12-17
- ModerateBisoprolol and hydrochlorothiazide tablets recalled over traces of another drug
FDA (Drugs) · 2025-12-10
Same hazard · subpotency
See all →- ModerateGood Neighbor Pharmacy Earwax Removal Drug Recalled for Low Potency
FDA (Drugs) · 2026-07-22
- ModerateNystatin Cream Recall Due to Low Potency Test Results
FDA (Drugs) · 2026-07-22
- ModerateFoster & Thrive Carbamide Peroxide 6.5% Recalled for Subpotent Strength
FDA (Drugs) · 2026-07-22
- ModerateLeader Carbamide Peroxide Earwax Removal Kit Recalled for Subpotency
FDA (Drugs) · 2026-07-22
- ModerateMeijer Earwax Removal Kit Recalled for Subpotent Active Ingredient
FDA (Drugs) · 2026-07-22